Lovastatin 복용 과정에 발생한 횡문근 융해증 1 예

Abstract

Lovastatin is an inhibitor of HMG-CoA reductase used to reduce total plasma cholesterol and LDL- cholesterol. Lovastatin is relatively well tolerated at usual dosage, and has a low incidence of adverse effects. Lovastatin like other Cholesterol-lowering agents can induce rhabdomyolysis and induce acute renal failure needing hemodialysis in severe cases. The myotoxicity has been attributed to an interference of biosynthesis of Coenzyme-Q or to a decrease in availavility of cholesterol for the formation and maintenance of muscle membranes. The duration of drug use, dosage, interaction with other drugs and associated disease are all thoughted to be of some importance in the pathogenesis of lovastatin induced myopathy. Recently we experienced a diabetic patient associated with hyperchoeisterolemia, who developed mild rhabdomyolysis after short period of low dose Lovastatin treatment, We report the case with the review of the literature.